ALK and non-small cell lung carcinoma: These observations suggest that—even when a pCR is achieved after salvage resection following preoperative alectinib—initially unresectable ALK-rearranged NSCLC remains prone to early distant relapse, highlighting the potential need for maintenance ALK-TKI therapy to reduce recurrence risk.